The opportunistic yeast Malassezia sympodialis belongs to the normal cutaneous flora but can also cause IgEmediated sensitization in patients suffering from atopic eczema (AE). We investigated 706 individuals by ImmunoCAPm70 and skin-prick tests with a crude M. sympodialis extract. In AE patients, we further performed skin prick tests, atopy patch tests, ELISA, and peripheral blood mononuclear cells proliferation assays with recombinant M. sympodialis allergens (rMala s 1 and 5-9). In 52/97 patients with AE-specific IgE against M. sympodialis was detectable. Almost no reactivity to M. sympodialis was seen in patients suffering from other allergic diseases (4/571) and no reactivity at all was seen in healthy controls (0/38). Skin tests showed variable recognition patterns against the different molecular structures with a predominant sensitization to rMala s 1, 5, 6, and 9, confirmed also by specific serum IgE to these allergens. Interestingly, IgE-and T-cell-mediated reactivity against M. sympodialis was also found in patients with the intrinsic form of AE. Thus, sensitization to M. sympodialis is specific for AE patients and occurs in both the extrinsic and intrinsic variant of eczema. Recombinant yeast allergens represent a useful tool to study molecular structures and differential sensitization patterns in the pathogenesis of AE.
INTRODUCTION
Atopic eczema (AE) is a chronically relapsing inflammatory skin disease, where the pathogenesis is not yet fully understood (Leung, 2000) . However, a combination of genetic background, deregulation of the immune system, a defective skin barrier, and environmental factors contribute to the development of AE (Leung and Bieber, 2003) . Approximately 80% of the adult AE patients show immediate-type skin reactions to environmental allergens together with elevated serum IgE levels. However, approximately 20% of patients with clinical signs of AE have low serum IgE levels and lack detectable specific serum IgE and positive skin prick test (SPT) reactions to such allergens. This subgroup is also defined as intrinsic, non-allergic AE or more recently non-atopic type of eczema (Oppel et al., 2000; Schmid-Grendelmeier et al., 2001; Johansson et al., 2004b) . As the serum level of IgE to aero-and food allergens in the extrinsic type can correlate with the severity of AE (Scalabrin et al., 1999) and increased number of IgE receptors are found on cutaneous antigenpresenting cells (Bruynzeel-Koomen et al., 1986; Bieber et al., 1992) , it can be postulated that allergens can be involved in the onset and/or maintenance of the disease.
Microorganisms have also been particularly emphasized as pathogenetic factors; in particular, Staphylococcus aureus and the skin colonizing opportunistic yeast Malassezia, earlier denoted as Pityrosporum (Jensen-Jarolim et al., 1992; Scalabrin et al., 1999; Scheynius et al., 2002) . Recently, such microorganisms have been postulated to be pathogenetically relevant also in a proportion of patients with the intrinsic form of AE . M. sympodialis has been reported as the most frequent species in both AE patients and healthy individuals (Sandstrom Falk et al., 2005) .
In previous studies, it was demonstrated that around 30-80% of patients with AE have positive SPT, positive atopy patch test (APT) reactions, and/or IgE antibodies against extract of Malassezia (Rokugo et al., 1990; Nissen et al., 1998; Mayser and Gross, 2000; Tengvall Linder et al., 2000; Zargari et al., 2001; Scheynius et al., 2002; Johansson et al., 2004a) . Proliferative responses of peripheral blood mononuclear cells (PBMCs) after stimulation with M. sympodialis extract are significantly higher in AE patients with Malassezia-specific serum IgE than in AE patients lacking Malassezia-specific serum IgE and in nonatopic healthy controls (Tengvall Linder et al., 1998; Johansson et al., 2002; Scheynius et al., 2002) . All these data indicate that the sensitization to M. sympodialis is a phenomenon specific for AE. However, studies in larger populations addressing this question are still lacking, namely also in intrinsic AE. Thus, we investigated the differential reactivity to M. sympodialis in various conditions, including various immediate-type allergic diseases, urticaria, and allergic contact dermatitis (ACD) (n ¼ 571) using SPT with natural extract and ImmunoCAPm70. Furthermore, we performed in the patient group with AE SPT, APT, ELISA, and a PBMC proliferation assay with the six recombinant M. sympodialis allergens rMala s 1 and rMala s 5-9 to further characterize particular allergens involved in both extrinsic and intrinsic AE.
RESULTS

Response to M. sympodialis extract
From all the 706 tested individuals (97 AE patients, 571 patients with other diseases, and 38 healthy controls), only the patient group with AE showed a high percentage of sensitization to natural M. sympodialis extract. In 52 of 97 patients (54%) with AE specific IgE reactivity against M. sympodialis extract was detected either serologically with the ImmunoCAPm70 system (median 18 kU/l, range 0.39-79.6 kU/l) or in SPT. From the 571 patients with other allergic diseases, only four patients (two with rhinoconjunctivitis, two with asthma bronchiale) showed a weak IgE reaction to M. sympodialis extract either in ImmunoCAPm70 or in SPT (Table 1) . The clinical investigation and the retrospective evaluation of the clinical history showed that two of these patients presented marginal signs for an AE and that the other two were previously afflicted with an AE. All healthy controls showed no IgE-mediated reaction to the M. sympodialis extract (Table 1 ). In the APT with M. sympodialis extract, 34 of the 69 tested AE patients (49%) showed a positive reaction (Table 3) . Even 12 of the 16 tested patients (75%) reacted positive in the PBMC proliferation assay to M. sympodialis extract (Table 3 ).
In vivo response to rMala s allergens Figure 1 shows the differential SPT and APT reactivity of the AE patients against the different recombinant M. sympodialis allergens with a predominance of sensitization to rMala s 1, rMala s 5, rMala s 6, and rMala s 9 in both types of skin tests.
Overall, 41 of 97 tested patients (42%) reacted to at least one rMala s protein (any rMala s) in the SPT, whereas 33 of 69 tested patients (48%) reacted to at least one rMala s protein (any rMala s) in the APT (Table 3) . These results were just a little bit below the positive reactions detected by the natural extract (46 and 49%, respectively).
In vitro response to rMala s allergens So far, the biological relevance of ELISA measurements of IgE reactivity with recombinant M. sympodialis allergens has not been determined. To assess the approximate cutoff values of the optical density (OD) for a given allergen in terms of biological activity, the quantitative OD measurements have to be correlated to the in vivo results. The patients were divided into four groups (SPT þ APT þ , SPT þ APTÀ, In this figure, we show the percentage of patients who reacted positive in the SPT (performed in all patients, n ¼ 97) or the APT (performed in n ¼ 69 patients) to rMala s allergens. SPT was considered as positive by a wheal diameter of X3 mm surrounded by erythema. APT was considered as positive when there was at least an erythema and infiltration ( þ ) after 48 and/or 72 hours.
www.jidonline.org 2415 SPTÀAPT þ , SPTÀAPTÀ) based on the in vivo tests to the natural extract. Because the mean OD of the SPT þ /APT þ tested patients was 0.9 and the mean OD of the SPTÀ/APTÀ tested patients was 0.09, we defined 0.3 as the limit for positive ELISA reactions for rMala s ( Figure S1 ). Overall, 53% (51/97) reacted to one of the recombinant M. sympodialis allergens with a predominance of sensitization to rMala s 1, rMala s 5, rMala s 6, and rMala s 9 (Table 3) . Almost no reaction to rMala s 7 and rMala s 8 was observed ( Figure 2 ). In the patient group, where we performed PBMC proliferation assays (n ¼ 16), we could induce a positive proliferation with all rMala s allergens, except for rMala s 5. A predominance of T-cell sensitization was seen to rMala s 1, rMala s 6, and rMala s 9. In all individuals of the negative control group (n ¼ 3), the PBMC proliferation assay was negative (Table 3) .
Intrinsic AE patient group
From the 97 patients with AE, 41 had a head-and-neck type whereas 56 had a more generalized form. Eighty-three were of the extrinsic type (36 with head-and-neck type) and 14 of the intrinsic type (five with head-and-neck type) ( Table 2) . All intrinsic AE patients had a total IgE level below 350 kU/l. Interestingly, also the patient group with the so-called intrinsic type of AE (because of the absence of specific IgE to the common aero-and food allergens) showed in vivo skin test reactivity to M. sympodialis extract (SPT 36%, APT 38%) and also to the different rMala s proteins except for rMala s 7 (Table 4 ). Furthermore, 7/14 (50%) showed positive Immu-noCAPm70 reactions, respective positive ELISA reactions to any rMala s proteins. In the PBMC proliferation assay, 5/8 (63%) reacted to the natural M. sympodialis extract. Also the rMala s allergens could induce a positive proliferation assay, except rMala s 5 and rMala s 7 (Table 4) .
DISCUSSION
Our study fully confirms in a large patient number that sensitization to M. sympodialis is found exclusively in patients with AE, but not in other hypersensitive diseases such as patients with inhalant, food or insect venom allergies, urticaria, or ACD. Thus, sensitization against M. sympodialis can be regarded as specific or almost pathognomonic for AE, both in generalized and in the head-and-neck type. According to the literature, where Malassezia-specific serum IgE was detected with a frequency of 32-68% and positive SPT to Malassezia was found in approximately 30-80% of AE patients (Nordvall et al., 1992; Scalabrin et al., 1999; Tengvall Linder et al., 2000; Zargari et al., 2001; Johansson et al., 2002; Scheynius et al., 2002) , we can confirm this type I sensitization in 53% (51/97) of the AE patients tested by the ImmunoCAPm70-system and in 46% (45/97) tested by SPT (Table 1) . Also in the APT, 49% (34/69) of the patients reacted positively to natural extract (Table 3) , this was in accordance with previous studies, where positive APT to Malassezia was found in 41-64% of the AE patients (Rokugo et al., 1990; Tengvall Linder et al., 2000; . It is not yet fully understood why sensitization against M. sympodialis occurs only in the patient group with AE, but not in patients with exclusively inhalant symptoms such as rhinoconjunctivitis and/or asthma. A possible cause is the high, long-standing cutaneous colonization with Malassezia. Antimicrobial peptides known as cathelicidins (LL-37) and beta-defensins (HBD-2) are deficient in skin lesions from patients with AE (Ong et al., 2002) , which might also contribute to a higher colonization with Malassezia in this patient group. Furthermore, the selective sensitization in AE patients might be favored by the disrupted skin barrier in AE. Whole yeast cells and allergenic components of the yeast are likely to pass the skin barrier and come in contact with professional antigen-presenting cells, such as Langerhans cells in the epidermis (Buentke et al., 2000 (Buentke et al., , 2001 . Antigen-presenting cells in the skin of AE patients also have an increased ability to react to those allergens (Gabrielsson et al., 2004) . Furthermore, skin-homing activated T-cells bearing the cutaneous lymphocytic antigen show increased reactivity in AE and may contribute to the formation of specific IgE (Akdis et al., 1997) . All these observations support the hypothesis that penetration of M. sympodialis in AE is possible and can induce an allergic reaction with a consequent production of specific IgE via B-cell stimulation in patients with AE.
Interestingly, also in the intrinsic type of AE, we found a high IgE-and T-cell-mediated sensitization to M. sympodialis (Table 4 ). These patients have neither associated respiratory Positive reaction in the PBMC assay were defined as stimulation index 42.5 (results obtained with an allergen concentration of 1 mg/ml after 6 days of cell culture are shown). or food allergies nor detectable IgE-mediated sensitization to common inhalant or food allergens. However, they also show a disrupted skin barrier and T cells from those patients equally respond to superantigen, staphylococcal enterotoxin B, and produce similar cytokines (Akdis et al., 1997; . One could speculate that this patient group -so far defined by the absence of sensitization to standard aero-/food allergens -is in fact a group of patients that nevertheless is at risk to get similarly sensitized to other agents with primary cutaneous exposure such as skin colonizing microbes as Staphylococci or Malassezia. As already described elsewhere, microbes such as M. sympodialis might indeed play a role as trigger factors also in intrinsic AE . The term intrinsic AE is therefore misleading to a certain extent (Johansson et al., 2004b) . Thus, our results also call into question the relevance of IgE in the pathogenesis of AE. Furthermore, we could show a very clear concordance on the one hand in vivo between SPT and APT (Figure 1) , and on the other hand between the in vivo and in vitro findings (Table 3) . Hence, 86% of the 51 ImmunoCAPm70-positive tested patients reacted positively in the SPT to natural extract, and 74% in the APT. This is most probably owing to the fact that the same allergen extract was used in all in vivo and in vitro tests (ATCC yeast strain no. 42132).
Malassezia extracts contain a wide range of IgE-binding components (Zargari et al., 1994; Lintu et al., 1997) , but variations in allergenic contents, difficulties in standardization of the extract (Zargari et al., 1995) as well as large batch to batch variation (Vailes et al., 2001; Zargari et al., 2001) may be solved by the use of highly pure recombinant proteins. By investigating in this study six of the known recombinant M. sympodialis allergens (rMala s 1 and rMala s 5-9) (Schmidt et al., 1997; Lindborg et al., 1999; Rasool et al., 2000; Andersson et al., 2004) , we found a strong correlation between positive SPT and APT to each recombinant allergen with a predominance of sensitization to rMala s 1, rMala s 5, rMala s 6, and rMala s 9 (Figure 1, Table 3 ). There was a significant reduced reaction to rMala s 7 in both in vivo tests (ATP and SPT), also detectable in the ELISA (Figure 2 ) and in the PBMC proliferation assay (Table 3) .
Of the recombinant M. sympodialis allergens used, only rMala s 5 and rMala s 6 show sequence similarity to other proteins; the others, rMala s 1, rMala s 7 to rMala s 9, are unique structures (Table S1 ). Hence owing to structural relationship of fungal manganese superoxide dismutase (rMala s11) with the human form of this enzyme, IgE-and T-cell-mediated autoreactivity can result in AE patients (Schmid-Grendelmeier et al., 2005) . Thus, high crossreactivity between rMala s 6 and human cyclophilin, a protein found in many organisms and proteins of human (Fluckiger et al., 2002) and showing the highest sensitization rate in our study (Table 3, Figure 2) , might also induce similar autoreactivity phenomens in AE.
In conclusion we could demonstrate in a large study population, that sensitization to M. sympodialis is highly specific for patients with AE and does not occur in patients with only inhalant allergies, urticaria, or ACD. Regarding the high frequency of sensitization to M. sympodialis, one could argue that these potential microbial allergens should be added in the diagnostic workup of AE patients, namely also in the intrinsic type of AE. This might be also relevant for therapeutic purposes, as various studies have reported beneficial effects of anti-fungals in some AE patients (Back et al., 1995; Back and Bartosik, 2001; Lintu et al., 2001; Ikezawa et al., 2004; Svejgaard et al., 2004) . Diagnosis with recombinant yeast allergens proved as a highly useful tool to further characterize the allergens involved, and to determine their clinical relevance in AE.
MATERIALS AND METHODS
Patient selection
Totally, 668 individuals with different allergic diseases (AE, allergic asthma, rhinitis and/or conjunctivitis, urticaria, food allergy, insect sting allergy, and ACD), and 38 healthy controls were investigated (Table 1) . Diagnosis of AE was made according to the criteria of Hanifin and Rajka (Hanifin, 1980) . Disease activity for AE was estimated using SCORAD (severity scoring of atopic dermatitis) (Consensus Report, 1993) . Furthermore, we divided the patients with AE in the clinical subtype of generalized or head-and-neck type of AE and also extrinsic and intrinsic type (Table 2) (Wü thrich, 1989; Johansson et al., 2001) . The group of intrinsic AE was defined by the absence of other atopic diseases such as allergic rhinoconjunctivitis or allergic bronchial asthma and a low or moderate total IgE level (o350 kU/l) in combination with negative in vitro IgE screening for aeroallergens and food allergens (e.g., sx1 and fx5, Pharmacia ImmunoCAP System, Pharmacia Diagnostics AB, Sweden). Patients with allergic rhinitis and/or conjunctivitis had all a typical history of seasonal or perennial symptoms and positive SPT with pollen or perennial allergens (house dust mites, animal dander from ALK, Denmark). All asthmatic subjects had in addition a history of wheezing and dyspnea during allergen exposure (American Thoracic Society, 1995) . Patients with food allergy showed a typical history of food-induced allergy and had either a positive SPT or detectable levels of food-specific serum IgE. Diagnosis in insect sting allergic patients was based on clinical history, intracutaneous skin tests, and specific IgE against bee or wasp venom in the serum (Pharmacia ImmunoCAP System). The urticaria diagnosis was carried out on the basis of clinical investigation and the typical history. Patients with ACD had a clear clinical history of contact dermatitis after exposure to a certain substance (such as nickel, cobaltchloride, and fragrance mix) and a corresponding positive patch test with the relevant substance, but no history or clinical signs of atopic dermatitis. Eleven out of the 13 patients had active ACD at the time of testing. Affected areas were in all cases areas other than the back tested and localized mostly to face or hands. The 38 healthy controls without clinical history of atopy were not sensitized to common allergens as controlled by SPT and serologic screenings (fx5 and sx1) and had a median total IgE of 50.6 kU/l (range 0.35-78). The study was approved by the Ethical Committee of the University of Zurich and was conducted according to the Declaration of Helsinki Principles. All patients and controls gave written informed consent.
Allergens and allergen extracts
A crude M. sympodialis (ATCC; Strain No. 42132) extract was prepared as described previously (Zargari et al., 1994) . Recombinant M. sympodialis allergens rMala s 1 and rMala s 5-9 were produced in Escherichia coli as described previously (Schmidt et al., 1997; Lindborg et al., 1999; Rasool et al., 2000; Andersson et al., 2004) . Limulus amebocyte lysate test for purity was performed and endotoxin doses (lipopolysaccharide) in all recombinant allergens and the natural extract were well under the cutoff value (Pedersen et al., 1994) .
Determination of total and allergen-specific IgE
Specific serum IgE to M. sympodialis extract (ImmunoCAPm70) and total serum IgE were determined for all patients and controls by the ImmunoCAP system as prescribed by the manufacturer (Pharmacia Diagnostics AB, Sweden). In the patient group with AE specific IgE to common inhalant allergens (sx1, Pharmacia) and food allergens (fx5, Pharmacia) were determined. IgE values X0.35 kU/l was defined as atopic sensitization. In addition, an ELISA was established to determine specific IgE to rMala s 1 and rMala s 5-9 as described previously (Moser et al., 1994) .
Skin tests
SPT was performed with M. sympodialis extract and with the recombinant allergens rMala s 1 and rMala s 5-9. The proteins were diluted in 0.9% sterile NaCl solution in a concentration of 100 mg/ ml. 0.9% NaCl and histamine hydrochloride 0.01% (ALK, Denmark) served as negative and positive control, respectively. All skin tests were performed in double on the volar forearm and applied in the two opposite directions, using Stallerpointe s devices (Trimedal, Switzerland). The tests were evaluated after 15 minutes. Wheals and flares were pen-marked and then transferred with scotch tape to a paper. The mean wheal diameter was calculated by the addition of the maximal longitudinal (d1) and transversal (d2) diameter divided by two [(d1 þ d2)/2]. A wheal diameter of X3 mm surrounded by erythema was considered positive.
APT was performed under open conditions in 69 AE patients and six healthy controls. No signs of eczema were allowed at the patch test sites (on the back). The skin was tape-stripped 10 times with scotch tape (2 cm, 3 M, Germany) as described previously (Darsow et al., 1995; Langeveld-Wildschut et al., 1995) . Thirty microliter of each recombinant allergen (rMala s 1 and rMala s 5-9) at a concentration of 100 mg/ml were applied on paper discs in Finn chambers (12 mm, Epitest Ltd, Hermal, Germany), in parallel with 30 ml M. sympodialis extract at a concentration of 5 mg/ml. NaCl 0.9% was used as a negative control. Oral corticosteroids were discontinued for at least 6 weeks before testing. Topical corticosteroids, calcinneurin inhibitors, or UV therapy had not been used in the last 3 weeks at test application sites. Reactions were read and documented after 48 and 72 hours by a dermatologist. The APT was considered as positive when there was at least an erythema and infiltration ( þ ) after 48 and/or 72 hours, according to the criteria of conventional contact allergy patch testing (Wilkinson et al., 1970) and corresponding at least with erythema and infiltration (a one þ reaction) considering the European Task force of atopic dermatitis (EFTAD) guidelines for atopy patch testing (Darsow et al., 2004) .
Proliferative response of PBMC
In 16 AE patients (eight extrinsic and eight intrinsic) and three healthy controls PBMCs were isolated from heparinized peripheral venous blood by Ficoll density gradient centrifugation, washed three times, and resuspended in Rosewell Park Memorial Institute media 1640 supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, 1% MEM non-essential amino acids and vitamins, 100 mg/ml streptomycin, 100 U/ml penicillin (all from Life Technologies, Switzerland), and 10% heat-inactivated fetal calf serum (Sera-Lab, UK). Samples of 5 Â 10 5 cells/100 ml were stimulated in round-bottomed 96-well plates with different concentrations, ranging from 0.01 to 10 mg/ml of rMala s 1 and rMala s 5-9 or M. sympodialis extract, respectively, in quadruplicates for 4 and 6 days. Phytohemagglutinin (10 mg/ml, Life Technologies, Switzerland) was used as a positive control and BSA served as a negative control. Proliferation was measured as incorporation of thymidine (DuPont-NEN, Switzerland) during the final 8 hours of culture. The results were expressed as mean c.p.m. for quadruplicates and as stimulation index calculated as mean c.p.m. for stimulated cells divided by mean c.p.m. for unstimulated cells. A stimulation index 42.5 was considered as positive.
